OMTM, Volume *20*

Supplemental Information

AAV9-mediated gene delivery of MCT1 to oligodendrocytes does not provide a therapeutic benefit in a mouse model of ALS

Caroline Eykens, Elisabeth Rossaert, Sandra Duqué, Laura Rué, André Bento-Abreu, Nicole Hersmus, Annette Lenaerts, Axelle Kerstens, Nikky Corthout, Sebastian Munck, Philip Van Damme, Matthew G. Holt, Georg von Jonquires, Matthias Klugmann, Ludo Van Den Bosch, and Wim Robberecht



Supplementary figure 1. Analysis of MCT1 expression in the sciatic nerve of wildtype mice following ICV delivery of the MBP-MCT1$^{Myc/Flag}$ -AAV9 vector. Immunofluorescent staining for Myc in longitudinal sciatic nerve sections of non-injected versus MBP-MCT1$^{Myc/Flag}$ -AAV9-injected mice.



Supplementary figure 2. MCT1 protein expression levels are reduced in the lumbar spinal cord of ALS mice as a function of disease. Western blot for the oligodendrocyte marker MCT1 in SOD1^{G93A} mice shows that MCT1 expression levels progressively decline relative to GAPDH with increasing age, starting from postnatal day 90 onwards. Data are presented as mean ± SEM, n = 5-8 mice per group and data are normalized to SOD1^{WT} P140. One-way ANOVA with Tukey's *post hoc* analysis, **p<0.01; ***p<0.001; ns = non-significant compared with SOD1^{WT} P140. E.S. = end-stage, between 150 and 160 days of age.